Olmetec Plus (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmetec Plus combines two agents that act on the renin‑angiotensin‑aldosterone system to lower blood pressure.

• Hypertension: helps achieve target blood pressure levels in adults.
• Heart failure with reduced ejection fraction: used as part of combination therapy to improve clinical outcomes.
• Diabetic nephropathy: provides renal protection by reducing intraglomerular pressure.

• Olmesartan medoxomil is a selective antagonist of the angiotensin II type 1 (AT1) receptor, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. Hydrochlorothiazide is a thiazide‑type diuretic that inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting natriuresis and reducing plasma volume. Together they produce additive blood‑pressure‑lowering effects.

Olmetec Plus may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue
• Increased urination
• Electrolyte disturbances (e.g., low potassium)
• Mild gastrointestinal discomfort

Serious or Rare Side Effects

• Severe hypotension
• Acute kidney injury
• Hyperkalemia
• Angio‑edema
• Liver function abnormalities
• Blood‑cell abnormalities such as neutropenia

Olmetec Plus should be used with caution in several clinical situations.

• Renal impairment: dose may need adjustment and renal function monitoring.
• Hepatic impairment: monitor liver enzymes regularly.
• Electrolyte imbalance: check serum potassium and sodium levels.
• Pregnancy: contraindicated in the second and third trimesters.
• Elderly patients: start at lower dose and monitor for orthostatic hypotension.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Olmetec Plus can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Aliskiren: combined use may increase risk of renal dysfunction and hyperkalemia.
• Potassium‑rich supplements or salts: may cause dangerous hyper‑kalaemia.
• Lithium: increased lithium levels and toxicity risk.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function.
• ACE inhibitors or other ARBs: additive risk of hyper‑kalaemia and renal impairment.
• Antidiabetic agents: may enhance glucose‑lowering effect, requiring dose adjustment.